Genzyme Restart Won’t Hobble Shire’s 2012 Prospects, Shire’s Gregoire Says
This article was originally published in The Pink Sheet Daily
Shire expects only a gradual pick up of competitive pressure from Genzyme's resumption of Fabrazyme manufacturing, with the double-digit growth of revenues in 2011 set to be replicated in 2012.
You may also be interested in...
While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.
The subsidiary of Sanofi long has pegged opening of additional plant as critical to restoring full production of Fabrazyme, which has been rationed to Fabry disease patients since a manufacturing interruption in 2009.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.